This study looks at the long-term safety and effectiveness of a medicine called pembrolizumab for people with advanced tumors. Participants are those who have been part of earlier studies using pembrolizumab and are now transitioning to this new study. The goal is to see how well pembrolizumab works over time and how safe it is for those who continue or start treatment.
The trial's ID number is NCT03486873. It is a Phase 3 study, which means it is looking closely at how well the treatment works and how safe it is. The study is regulated by the FDA and aims to include about 3,500 participants.
Who can join
Adults aged 18 and older can join this study. It is open to men and women who have been treated with pembrolizumab or similar medicines in prior studies. Participants must have good organ function and be free of any serious treatment side effects. Certain health conditions may prevent participation, but the trial team will confirm eligibility.
Conditions
Solid Tumors, Hematologic Malignancies
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive pembrolizumab through an IV, either 200 mg or 400 mg, depending on their treatment group. Some may also receive other treatments like lenvatinib or olaparib. Participants are placed into different groups based on their previous treatment phases, and everyone will have regular check-ups and treatments based on their group.
Where
This trial is enrolling at 65 locations. Recruiting sites are listed first.
Arizona Cancer Center at UMC North ( Site 0018)
Tucson, Arizona
Recruiting
Augusta University ( Site 0077)
Augusta, Georgia
Recruiting
Blue Ridge Cancer Care ( Site 0067)
Roanoke, Virginia
Recruiting
Cancer Institute of New Jersey ( Site 0025)
New Brunswick, New Jersey
Recruiting
Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054)
Bakersfield, California
Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0043)